Immunogenicity	B:C4277607
of	O
a	O
DNA	O
Vaccine	I:C0376613
Encoding	O
Ag85a	O
-	O
Tb10.4	O
Antigens	I:C1570563
from	O
Mycobacterium	O
Tuberculosis	I:C0026926
.	O

Immunogenicity	O
of	O
a	O
DNA	B:C0376613
Vaccine	I:C0376613
Encoding	O
Ag85a	O
-	O
Tb10.4	O
Antigens	I:C1570563
from	O
Mycobacterium	O
Tuberculosis	I:C0026926
.	O

Immunogenicity	O
of	O
a	O
DNA	O
Vaccine	I:C0376613
Encoding	O
Ag85a	B:C0675617
-	O
Tb10.4	O
Antigens	I:C1570563
from	O
Mycobacterium	O
Tuberculosis	I:C0026926
.	O

Immunogenicity	O
of	O
a	O
DNA	O
Vaccine	I:C0376613
Encoding	O
Ag85a	O
-	O
Tb10.4	B:C1570563
Antigens	I:C1570563
from	O
Mycobacterium	O
Tuberculosis	I:C0026926
.	O

Immunogenicity	O
of	O
a	O
DNA	O
Vaccine	I:C0376613
Encoding	O
Ag85a	O
-	O
Tb10.4	O
Antigens	I:C1570563
from	O
Mycobacterium	B:C0026926
Tuberculosis	I:C0026926
.	O

Tuberculosis	B:C0041296
is	O
a	O
life	O
threatening	I:C2826244
disease	O
that	O
is	O
partially	O
prevented	O
by	O
BCG	O
vaccine	I:C0004886
.	O

Tuberculosis	O
is	O
a	O
life	B:C2826244
threatening	I:C2826244
disease	O
that	O
is	O
partially	O
prevented	O
by	O
BCG	O
vaccine	I:C0004886
.	O

Tuberculosis	O
is	O
a	O
life	O
threatening	I:C2826244
disease	B:C0012634
that	O
is	O
partially	O
prevented	O
by	O
BCG	O
vaccine	I:C0004886
.	O

Tuberculosis	O
is	O
a	O
life	O
threatening	I:C2826244
disease	O
that	O
is	O
partially	O
prevented	B:C0150638
by	O
BCG	O
vaccine	I:C0004886
.	O

Tuberculosis	O
is	O
a	O
life	O
threatening	I:C2826244
disease	O
that	O
is	O
partially	O
prevented	O
by	O
BCG	B:C0004886
vaccine	I:C0004886
.	O

Development	B:C0597634
of	O
more	O
effective	O
vaccines	O
is	O
an	O
urgent	O
priority	O
in	O
TB	O
control	O
.	O

Development	O
of	O
more	O
effective	O
vaccines	B:C0042210
is	O
an	O
urgent	O
priority	O
in	O
TB	O
control	O
.	O

Development	O
of	O
more	O
effective	O
vaccines	O
is	O
an	O
urgent	O
priority	O
in	O
TB	B:C0041296
control	O
.	O

Ag85a	B:C0675617
and	O
Tb10.4	O
are	O
the	O
members	O
of	O
culture	O
filter	I:C0033684
protein	I:C0033684
(	O
culture	O
filter	I:C0033684
protein	I:C0033684
)	O
of	O
M.	O
tuberculosis	I:C0026926
that	O
have	O
high	O
immunogenicity	O
.	O

Ag85a	O
and	O
Tb10.4	B:C1570563
are	O
the	O
members	O
of	O
culture	O
filter	I:C0033684
protein	I:C0033684
(	O
culture	O
filter	I:C0033684
protein	I:C0033684
)	O
of	O
M.	O
tuberculosis	I:C0026926
that	O
have	O
high	O
immunogenicity	O
.	O

Ag85a	O
and	O
Tb10.4	O
are	O
the	O
members	O
of	O
culture	B:C0033684
filter	I:C0033684
protein	I:C0033684
(	O
culture	O
filter	I:C0033684
protein	I:C0033684
)	O
of	O
M.	O
tuberculosis	I:C0026926
that	O
have	O
high	O
immunogenicity	O
.	O

Ag85a	O
and	O
Tb10.4	O
are	O
the	O
members	O
of	O
culture	O
filter	I:C0033684
protein	I:C0033684
(	O
culture	B:C0033684
filter	I:C0033684
protein	I:C0033684
)	O
of	O
M.	O
tuberculosis	I:C0026926
that	O
have	O
high	O
immunogenicity	O
.	O

Ag85a	O
and	O
Tb10.4	O
are	O
the	O
members	O
of	O
culture	O
filter	I:C0033684
protein	I:C0033684
(	O
culture	O
filter	I:C0033684
protein	I:C0033684
)	O
of	O
M.	B:C0026926
tuberculosis	I:C0026926
that	O
have	O
high	O
immunogenicity	O
.	O

Ag85a	O
and	O
Tb10.4	O
are	O
the	O
members	O
of	O
culture	O
filter	I:C0033684
protein	I:C0033684
(	O
culture	O
filter	I:C0033684
protein	I:C0033684
)	O
of	O
M.	O
tuberculosis	I:C0026926
that	O
have	O
high	O
immunogenicity	B:C4277607
.	O

To	O
analyze	B:C0936012
the	O
immunogenicity	O
of	O
Ag85a	O
-	O
Tb10.4	O
DNA	O
vaccine	I:C0376613
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
)	O
.	O

To	O
analyze	O
the	O
immunogenicity	B:C4277607
of	O
Ag85a	O
-	O
Tb10.4	O
DNA	O
vaccine	I:C0376613
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
)	O
.	O

To	O
analyze	O
the	O
immunogenicity	O
of	O
Ag85a	B:C0675617
-	O
Tb10.4	O
DNA	O
vaccine	I:C0376613
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
)	O
.	O

To	O
analyze	O
the	O
immunogenicity	O
of	O
Ag85a	O
-	O
Tb10.4	B:C1570563
DNA	O
vaccine	I:C0376613
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
)	O
.	O

To	O
analyze	O
the	O
immunogenicity	O
of	O
Ag85a	O
-	O
Tb10.4	O
DNA	B:C0376613
vaccine	I:C0376613
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
)	O
.	O

To	O
analyze	O
the	O
immunogenicity	O
of	O
Ag85a	O
-	O
Tb10.4	O
DNA	O
vaccine	I:C0376613
by	O
enzyme	B:C0014441
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
(	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
)	O
.	O

To	O
analyze	O
the	O
immunogenicity	O
of	O
Ag85a	O
-	O
Tb10.4	O
DNA	O
vaccine	I:C0376613
by	O
enzyme	O
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
(	O
enzyme	B:C0014441
-	I:C0014441
linked	I:C0014441
immunosorbent	I:C0014441
assay	I:C0014441
)	O
.	O

In	O
this	O
study	B:C2603343
a	O
previously	O
described	O
plasmid	O
DNA	O
vaccine	I:C0376613
encoding	O
Ag85a	O
-	O
Tb10.4	O
was	O
used	O
to	O
examine	O
its	O
capability	O
in	O
the	O
stimulation	O
of	O
immune	O
responses	I:C0301872
in	O
an	O
animal	O
model	I:C0599779
.	O

In	O
this	O
study	O
a	O
previously	O
described	O
plasmid	O
DNA	B:C0376613
vaccine	I:C0376613
encoding	O
Ag85a	O
-	O
Tb10.4	O
was	O
used	O
to	O
examine	O
its	O
capability	O
in	O
the	O
stimulation	O
of	O
immune	O
responses	I:C0301872
in	O
an	O
animal	O
model	I:C0599779
.	O

In	O
this	O
study	O
a	O
previously	O
described	O
plasmid	O
DNA	O
vaccine	I:C0376613
encoding	O
Ag85a	B:C0675617
-	O
Tb10.4	O
was	O
used	O
to	O
examine	O
its	O
capability	O
in	O
the	O
stimulation	O
of	O
immune	O
responses	I:C0301872
in	O
an	O
animal	O
model	I:C0599779
.	O

In	O
this	O
study	O
a	O
previously	O
described	O
plasmid	O
DNA	O
vaccine	I:C0376613
encoding	O
Ag85a	O
-	O
Tb10.4	B:C1570563
was	O
used	O
to	O
examine	O
its	O
capability	O
in	O
the	O
stimulation	O
of	O
immune	O
responses	I:C0301872
in	O
an	O
animal	O
model	I:C0599779
.	O

In	O
this	O
study	O
a	O
previously	O
described	O
plasmid	O
DNA	O
vaccine	I:C0376613
encoding	O
Ag85a	O
-	O
Tb10.4	O
was	O
used	O
to	O
examine	B:C0936012
its	O
capability	O
in	O
the	O
stimulation	O
of	O
immune	O
responses	I:C0301872
in	O
an	O
animal	O
model	I:C0599779
.	O

In	O
this	O
study	O
a	O
previously	O
described	O
plasmid	O
DNA	O
vaccine	I:C0376613
encoding	O
Ag85a	O
-	O
Tb10.4	O
was	O
used	O
to	O
examine	O
its	O
capability	O
in	O
the	O
stimulation	O
of	O
immune	B:C0301872
responses	I:C0301872
in	O
an	O
animal	O
model	I:C0599779
.	O

In	O
this	O
study	O
a	O
previously	O
described	O
plasmid	O
DNA	O
vaccine	I:C0376613
encoding	O
Ag85a	O
-	O
Tb10.4	O
was	O
used	O
to	O
examine	O
its	O
capability	O
in	O
the	O
stimulation	O
of	O
immune	O
responses	I:C0301872
in	O
an	O
animal	B:C0599779
model	I:C0599779
.	O

Female	O
BALB	B:C0025919
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	B:C0042196
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	B:C0034862
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	B:C0017397
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	B:C0442117
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	B:C0079189
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	B:C0021745
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	B:C0123759
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	B:C0021758
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
were	O
measured	O
.	O

Female	O
BALB	O
/	I:C0025919
c	I:C0025919
mice	I:C0025919
were	O
vaccinated	O
with	O
100	O
μg	O
of	O
purified	O
recombinant	O
vector	O
intramuscularly	O
3	O
times	O
at	O
two	O
-	O
week	O
intervals	O
and	O
the	O
levels	O
of	O
five	O
cytokines	O
including	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0123759
12	I:C0123759
,	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	B:C0040690
-β	I:C0040690
were	O
measured	O
.	O

The	O
levels	O
of	O
IFN	B:C0021745
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
for	O
the	O
mice	O
following	O
immunization	O
with	O
Ag85A	O
-	O
Tb10.4	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
BCG	O
and	O
control	O
group	O
(	O
p<0.05	O
)	O
.	O

The	O
levels	O
of	O
IFN	O
-γ	I:C0021745
and	O
IL	B:C0123759
-	I:C0123759
12	I:C0123759
for	O
the	O
mice	O
following	O
immunization	O
with	O
Ag85A	O
-	O
Tb10.4	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
BCG	O
and	O
control	O
group	O
(	O
p<0.05	O
)	O
.	O

The	O
levels	O
of	O
IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
for	O
the	O
mice	B:C0025919
following	O
immunization	O
with	O
Ag85A	O
-	O
Tb10.4	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
BCG	O
and	O
control	O
group	O
(	O
p<0.05	O
)	O
.	O

The	O
levels	O
of	O
IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
for	O
the	O
mice	O
following	O
immunization	B:C0020971
with	O
Ag85A	O
-	O
Tb10.4	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
BCG	O
and	O
control	O
group	O
(	O
p<0.05	O
)	O
.	O

The	O
levels	O
of	O
IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
for	O
the	O
mice	O
following	O
immunization	O
with	O
Ag85A	B:C0675617
-	O
Tb10.4	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
BCG	O
and	O
control	O
group	O
(	O
p<0.05	O
)	O
.	O

The	O
levels	O
of	O
IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
for	O
the	O
mice	O
following	O
immunization	O
with	O
Ag85A	O
-	O
Tb10.4	B:C1570563
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
BCG	O
and	O
control	O
group	O
(	O
p<0.05	O
)	O
.	O

The	O
levels	O
of	O
IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
for	O
the	O
mice	O
following	O
immunization	O
with	O
Ag85A	O
-	O
Tb10.4	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
the	O
BCG	B:C0004886
and	O
control	O
group	O
(	O
p<0.05	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
IL	B:C0021758
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
between	O
groups	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
and	O
TGF	O
-β	I:C0040690
between	O
groups	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
levels	O
of	O
IL	O
-	I:C0021758
4	I:C0021758
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
TGF	B:C0040690
-β	I:C0040690
between	O
groups	O
.	O

IFN	B:C0021745
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	O
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	B:C0123759
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	O
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	B:C0079189
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	O
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	B:C0079189
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	O
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	B:C0025919
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	O
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	B:C0042196
with	O
Ag85a	O
-	O
TB10.4	O
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	B:C0675617
-	O
TB10.4	O
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	B:C1570563
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	O
DNA	B:C0376613
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	O
groups	O
.	O

IFN	O
-γ	I:C0021745
and	O
IL	O
-	I:C0123759
12	I:C0123759
Th1	O
cytokines	O
increased	O
significantly	O
in	O
mice	O
vaccinated	O
with	O
Ag85a	O
-	O
TB10.4	O
DNA	O
vaccine	I:C0376613
in	O
comparison	O
to	O
the	O
control	O
and	O
BCG	B:C0004886
groups	O
.	O

Our	O
results	O
may	O
serve	O
as	O
a	O
groundwork	O
for	O
further	O
research	B:C0035168
into	O
the	O
prevention	O
and	O
treatment	O
of	O
tuberculosis	O
.	O

Our	O
results	O
may	O
serve	O
as	O
a	O
groundwork	O
for	O
further	O
research	O
into	O
the	O
prevention	O
and	O
treatment	B:C0087111
of	O
tuberculosis	O
.	O

Our	O
results	O
may	O
serve	O
as	O
a	O
groundwork	O
for	O
further	O
research	O
into	O
the	O
prevention	O
and	O
treatment	O
of	O
tuberculosis	B:C0041296
.	O

